Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Rigel Pharmaceuticals Inc. is managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, providing a variety of perspectives during the examination process. The company's prosecution efforts are focused within 2 distinct art units. COLEMAN, BRENDA LIBBY is the busiest examiner, currently holding 1 pending action.
With 4 pending office actions and 4 different examiners, the portfolio's progress is not tied to the performance of a single individual. The 2 distinct art units suggest that the Biotechnology & Pharmaceuticals technologies are being reviewed in at least two different specialized areas of the patent office. Practitioners should monitor the pending actions for consistency in rejections, especially since they are concentrated in the art units. This level of activity reflects an ongoing investment in the Biotechnology & Pharmaceuticals sector. Because COLEMAN, BRENDA LIBBY has 1 pending action, the workload is distributed across the examiner pool. Practitioners should focus on the specific requirements of the distinct art units to optimize their strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18745814 | FORMULATIONS AND DOSING REGIMENS FOR RIP1 KINASE INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | KIFLE, BRUCK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18890094 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | COLEMAN, BRENDA LIBBY | — |
| 18745814 | FORMULATIONS AND DOSING REGIMENS FOR RIP1 KINASE INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | KIFLE, BRUCK | — |
| 18690705 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | WELLS, LAUREN QUINLAN | — |
| 18334608 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | MCDOWELL, BRIAN E | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18890094 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | COLEMAN, BRENDA LIBBY | — | §112DP | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18745814 | FORMULATIONS AND DOSING REGIMENS FOR RIP1 KINASE INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | KIFLE, BRUCK | — | §103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18690705 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | WELLS, LAUREN QUINLAN | 1622 | §102§103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18334608 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | MCDOWELL, BRIAN E | 1624 | §102 | Final Rejection | — | Pending | Jun 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial